Angiotensin Peptides Potentiate SARS-CoV-2 Spike Protein–AXL Interactions: Mechanistic Insights and Research Applications

Study Background and Research Question

The renin–angiotensin system (RAS) is central to cardiovascular physiology, with angiotensin peptides orchestrating blood pressure and fluid balance. The COVID-19 pandemic, driven by SARS-CoV-2, has drawn intense focus to angiotensin-converting enzyme 2 (ACE2) as the virus’s primary cellular entry point. However, emerging evidence implicates additional receptors, such as neuropilin-1 (NRP1) and AXL, in viral entry, especially in tissues with low ACE2 expression. The reference study by Oliveira et al. (Int. J. Mol. Sci. 2025, 26, 6067) addresses a previously unexplored question: Do naturally occurring angiotensin peptides modulate SARS-CoV-2 spike protein binding to its entry receptors, and what are the mechanistic implications for both viral pathogenesis and RAS biology?

Key Innovation from the Reference Study

Oliveira et al. provide the first systematic demonstration that endogenous angiotensin peptides, including truncated forms such as Angiotensin 1/2 (5-7), can significantly enhance the binding affinity of the SARS-CoV-2 spike protein to the AXL receptor. This work advances the field by mapping how specific peptide sequences and structural modifications—such as N- and C-terminal truncations and tyrosine modifications—govern the potentiation of spike–AXL interactions. The findings suggest that the RAS, beyond its canonical roles in blood pressure regulation, may directly influence viral entry mechanisms and COVID-19 pathogenesis.

Methods and Experimental Design Insights

The authors employed antibody-based binding assays to quantify the interaction between SARS-CoV-2 spike protein and three host receptors: ACE2, NRP1, and AXL. They tested full-length and truncated angiotensin peptides, including Angiotensin I (1–10), Angiotensin II (1–8), Angiotensin (1–7), and shorter fragments down to Angiotensin (5–7) (corresponding to the H2N-Ile-His-Pro-OH peptide). The study also evaluated the effects of site-specific modifications, such as tyrosine to valine substitution and tyrosine phosphorylation at position 4 of the peptide chain. Quantitative binding data were generated to assess how each peptide variant influenced spike protein affinity for the different receptors.

Core Findings and Why They Matter

The study’s central discovery is that truncated angiotensin peptides—including Angiotensin (5–7)—robustly enhance spike–AXL binding, with some variants increasing binding up to 2.7-fold. Notably, C-terminal deletions (from Angiotensin II to Angiotensin (1–7) or (1–6)) retained the ability to potentiate spike–AXL interactions, while N-terminal truncations (to Angiotensin (2–8), Angiotensin IV (3–8), (2–7), and (5–7)) produced even more pronounced effects. Modifications at tyrosine position 4 (Y4V substitution or phosphorylation) further amplified spike–AXL binding. While the enhancement was most prominent for AXL, Angiotensin IV also increased spike binding to ACE2 and NRP1. These results indicate that specific peptide fragments of the RAS can allosterically regulate viral receptor engagement (see reference study)—a mechanistic insight with implications for both hypertension research peptides and antiviral therapeutic strategies.

This mechanistic bridge is particularly relevant because AXL is highly expressed in respiratory cells with low ACE2, suggesting a potential route for SARS-CoV-2 infection independent of classical ACE2 pathways. The findings therefore illuminate a new intersection between peptide hormone vasoconstriction, blood pressure regulation peptides, and viral host cell entry.

Comparison with Existing Internal Articles

Several recent articles have contextualized and expanded the significance of these findings for renin-angiotensin system research. For instance, the article "Angiotensin 1/2 (5-7): Mechanistic Insights and Strategic..." analyzes the dual roles of this H2N-Ile-His-Pro-OH peptide as both a potent vasoconstrictor and as an enhancer of viral receptor binding, integrating evidence from the Oliveira et al. study to recommend translational research strategies. Similarly, "Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding" provides a focused synthesis that highlights the relevance of truncated angiotensin peptides—such as Angiotensin 1/2 (5-7)—for understanding the cross-talk between cardiovascular regulation and SARS-CoV-2 pathogenesis. These sources reinforce the core message that blood pressure regulation peptides are now implicated in viral research domains, offering new avenues for both mechanistic and translational studies.

Limitations and Transferability

While the study employs robust in vitro binding assays, several limitations merit consideration. First, the experiments do not directly demonstrate enhanced viral infectivity or pathogenesis in live-cell or in vivo models; the outcomes are restricted to receptor-peptide-spike binding dynamics. Second, the concentrations of peptides used may not precisely recapitulate physiological or pathophysiological levels in human tissues during infection or hypertension. Third, the study does not address downstream cellular consequences—such as changes in viral replication, immune response, or tissue injury—arising from enhanced spike–AXL engagement. Transferability to clinical scenarios therefore remains to be established, and future research should examine these effects in more complex biological systems.

Why this cross-domain matters, maturity, and limitations

This research establishes a critical mechanistic bridge between the renin–angiotensin system and viral entry pathways. By demonstrating that angiotensin-derived peptides can enhance SARS-CoV-2 spike protein binding to AXL and, to a lesser extent, ACE2 and NRP1, the study suggests that RAS modulation could influence susceptibility or severity of COVID-19. However, the maturity of this cross-domain insight is currently limited by the lack of in vivo validation and incomplete understanding of the tissue and disease context. Researchers should interpret these findings as hypothesis-generating rather than definitive evidence for clinical translation.

Research Support Resources

To facilitate high-fidelity experimentation in this emerging intersection of cardiovascular and viral research, reliable reagents are essential. Researchers can incorporate Angiotensin 1/2 (5-7) (SKU A1049), a synthetic H2N-Ile-His-Pro-OH peptide with confirmed purity and solubility, into experimental workflows that require precise manipulation of RAS-derived fragments in biochemical or cell-based assays. For detailed solubility and storage recommendations, consult the product dossier and related technical resources.

Protocol Parameters

• Peptide dissolution: Dissolve Angiotensin 1/2 (5-7) at ≥36.5 mg/mL in DMSO, or ≥50 mg/mL in ethanol or water, as per product information; use freshly prepared solutions for best results in binding or signaling assays.
• Binding assay setup: Employ antibody-based binding platforms to quantify spike–receptor interaction in the presence of angiotensin peptide concentrations matched to those tested in the reference study (typically micromolar range; adjust according to assay sensitivity).
• Storage: Store peptide aliquots as solids at -20°C for optimal stability; minimize freeze-thaw cycles.
• Experimental controls: Include full-length and truncated angiotensin peptides to map sequence–activity relationships, as outlined by Oliveira et al.

Outlook

The evidence that RAS peptides such as Angiotensin 1/2 (5-7) modulate SARS-CoV-2 receptor binding opens promising new avenues in both hypertension and COVID-19 research. As detailed by Oliveira et al., further studies are needed to clarify in vivo relevance, therapeutic potential, and the impact on disease phenotypes. For now, these findings provide a mechanistic rationale for integrating blood pressure regulation peptides into viral pathogenesis models, supporting a new generation of interdisciplinary investigations.